Dr. Florence Camatte: GLP-1s and Longevity

Almost everyone alive today is carrying a memory of hunger they never personally lived through. That is the strange premise Dr. Florence Camatte opens with: nearly every human being inherited a body built by ancestors who survived famine, whether the Irish famine or an earlier one, and that inheritance is still running the show (02:58). Camatte is not a biohacker with a podcast feed and a theory. She trained at the National Institutes of Health and spent twenty five years on the Yale faculty, where she founded the Women's Health Research Center (00:25). Her claim, stated flatly, is that she has never once seen a patient with an optimal fasting glucose, fasting insulin, and hemoglobin A1C all at the same time. Not one.

"I haven't met one person with an optimal fasting sugar, fasting insulin, or hemoglobin A1C in combination. Not one." — Dr. Florence Camatte [03:23]

That single observation is the spine of the whole conversation. If nearly every adult has some degree of what Camatte calls a disorder of carbohydrate metabolism, the inability to handle sugar the way a healthy body should, then a lot of what gets filed under separate diseases, heart attack, stroke, dementia, even osteoporosis, may really be downstream effects of the same glucose problem working on different organs (03:23). That reframing is also why Camatte describes GLP-1 drugs, the class that includes Mounjaro and works by mimicking a gut hormone that signals fullness to the brain, as the modern equivalent of antibiotics.

"GLP-1s are the antibiotics of the 21st century, because it's antibiotics that in the 20th century, that kept us living longer." — Dr. Florence Camatte [01:12]

The hormone itself is not synthetic in origin. GLP-1 is something the body already makes, starting in a hunger-regulating region of the brain called the arcuate nucleus, and it touches nearly every organ system once it is amplified by a drug (02:05). Liz Moody points to trial data showing a 20 percent drop in heart attacks and strokes and a 24 percent drop in kidney failure among people using these drugs (01:12), and Camatte has personal skin in the game: she has used a GLP-1 herself since the first one reached the market twenty one years ago, partly because her own kidney function, like her identical twin's, improved on it (06:05).

None of this is presented as a free lunch. Camatte is specific about where the drugs go wrong. Teenagers and young women who were already under-fed, she says, can lose bone density they never built in the first place, since bone needs protein, calcium, and vitamin D to turn over and GLP-1 induced appetite loss can starve that process (07:01). She also flags a narrow but real danger: anyone with a family history of medullary thyroid cancer should not take these drugs, because the genetic risk is the kind of thing a prescription cannot outweigh (07:43). The lesson is not that GLP-1s are risk-free. It is that the risk calculation should start with a person's actual biology rather than a cultural panic in either direction.

Five Numbers Worth Asking For

Camatte's practical answer to "should I take this" is not a drug question at all. It is a testing question. She recommends five biomarkers that most doctors do not order as a set: fasting glucose, hemoglobin A1C (a measure of average blood sugar over roughly one hundred days), fasting insulin, a cholesterol risk ratio, and free testosterone (08:46). Fasting insulin is the one she says is most neglected and most revealing: in a healthy system, insulin should read close to zero three hours after a meal, yet she regularly sees it still elevated the next morning, which is an early signature of insulin resistance that can show up decades before a diabetes diagnosis (09:06). Free testosterone makes the list because, in her telling, it is the first hormone to decline in both men and women once they hit their thirties, which sets off a chain reaction: less muscle, more fat around the middle, and faster bone loss (09:38).

That is also why she calls muscle "the organ of longevity" (12:34): muscle tissue absorbs and stores circulating sugar, so losing it compounds the same glucose problem the drugs are trying to fix. Her baseline prescription for protecting muscle, independent of any drug, is at least one gram of protein per kilogram of body weight alongside regular resistance training (15:08). For women specifically, she targets a free testosterone level between 6 and 30, adjusted to how a given patient actually feels and functions rather than to a lab's population average, since she argues reference ranges reflect a broad, often unwell population rather than an optimal one (16:48). She has taken testosterone herself since her thirties, originally prompted by watching two aunts die from osteoporosis complications, and now prescribes it to most of her patients (17:29).

Smaller, odder claims thread through the same logic. She says brushing teeth three times a day is linked to a lower heart attack risk than brushing once, because oral bacteria entering the bloodstream can affect heart valves (40:52). She describes vitamin D not as a vitamin at all but as a fat-soluble steroid hormone central to immune function, and pairs it with vitamin K2 for calcium absorption (43:53). And for anyone determined to eat a dessert anyway, her workaround is sequencing: eat protein, fat, and fiber, a handful of nuts will do, before the sugar hits, which blunts the resulting glucose spike without requiring anyone to give up the treat entirely (48:32).

What Sleep Buys That The Gym Cannot

If testosterone and glucose are the daytime story, sleep is the one Camatte will not compromise on. Liz Moody cites research, including work by Stanford geneticist Michael Snyder, showing a sharp jump in biological aging around age 44 and again around 60, driven in part by the hormonal shifts already discussed (57:26). Her own rule for travelers and overworked patients who pride themselves on hitting the gym after midnight on four hours of sleep is blunt.

"Sleep trumps your gym. So don't worry about working out if you haven't gotten quality sleep." — Dr. Florence Camatte [82:18]

The mechanism she gives is straightforward: sleep is when growth hormone rises and cortisol falls, the nightly reset that a hard workout cannot substitute for. For patients whose sleep is disrupted by hormonal change, particularly women in perimenopause, she often reaches for trazodone, a low-dose prescription sleep aid that she says works immediately when it works, in roughly 60 to 70 percent of the people she tries it on (55:46).

At the far, expensive edge of the conversation sits therapeutic plasma exchange, a procedure where plasma is removed from one arm, cleaned, and the red blood cells returned through the other, a less dramatic cousin of the young-blood-for-old-blood idea that tech entrepreneur Bryan Johnson pursued using his own son's blood (70:34). Camatte tried it on herself starting about five years ago, one treatment a month for three months, and reports her own biological age measures improved by fifteen years on the trend line she tracks, at a cost of ten to fifteen thousand dollars per treatment (71:03). She is careful to call it promising rather than proven, noting ongoing research into its effects on Alzheimer's risk and on clearing microplastics from the body (71:24).

What ties all of this together, the testing, the testosterone, the drugs, the sleep rules, is a line Camatte returns to near the start of the conversation: she thinks of DNA as a draft, something that can be edited by the way a person chooses to live (30:03). Ancestors who survived famine handed down bodies built for scarcity, in a world that no longer runs on scarcity. The five biomarkers are simply a way of reading that inherited draft before deciding what to change.